Status:
WITHDRAWN
Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer
Lead Sponsor:
Sharp HealthCare
Conditions:
Metastatic Prostate Cancer
Eligibility:
MALE
18-75 years
Phase:
NA
Brief Summary
The investigators aim to test the safety and feasibility of prostate gland stereotactic body radiotherapy (SBRT) plus best systemic therapy in newly diagnosed metastatic prostate cancer.
Detailed Description
The investigators and other investigators have previously documented the safety and efficacy of definitive intent stereotactic body radiotherapy (SBRT) in the treatment of localized prostate cancer. ...
Eligibility Criteria
Inclusion
- Histologically-confirmed, adenocarcinoma of the prostate
- Clinical Stage T1b - T4, NX-0-1, M1
- Any Gleason score
- PSA\<1000
- ECOG Performance Status 0-2
- No prior prostate radiation or other definitive therapy
Exclusion
- Prior prostatectomy or cryotherapy of the prostate
- Prior radiotherapy to the prostate or lower pelvis
- Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion
- Chemotherapy for a malignancy in the last 5 years
- History of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years
Key Trial Info
Start Date :
July 16 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 17 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02206724
Start Date
July 16 2014
End Date
April 17 2018
Last Update
April 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sharp Healthcare
San Diego, California, United States, 92123